Fiacitabine has been used in trials studying the treatment of HIV Infections and Cytomegalovirus Infections.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Rubella virus vaccine | The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Fiacitabine. |
| Bacillus calmette-guerin substrain tice live antigen | The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Fiacitabine. |
| Bacillus calmette-guerin substrain connaught live antigen | The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Fiacitabine. |
| Yellow fever vaccine | The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Fiacitabine. |
| Anthrax vaccine | The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Fiacitabine. |
| Typhoid Vaccine Live | The therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Fiacitabine. |
| BCG vaccine | The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Fiacitabine. |
| Human adenovirus e serotype 4 strain cl-68578 antigen | The therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Fiacitabine. |
| Vibrio cholerae CVD 103-HgR strain live antigen | The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Fiacitabine. |
| Adenovirus type 7 vaccine live | The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Fiacitabine. |
| Varicella zoster vaccine (live/attenuated) | The therapeutic efficacy of Varicella zoster vaccine (live/attenuated) can be decreased when used in combination with Fiacitabine. |
| Bacillus calmette-guerin substrain russian BCG-I live antigen | The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Fiacitabine. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Fiacitabine. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Fiacitabine. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Fiacitabine. |
| Methoxy polyethylene glycol-epoetin beta | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Fiacitabine. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Lidocaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Ropivacaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Bupivacaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Cinchocaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Dyclonine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Procaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Prilocaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Proparacaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Meloxicam. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Oxybuprocaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Cocaine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Mepivacaine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Levobupivacaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Diphenhydramine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Benzocaine. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Chloroprocaine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Phenol. |
| Tetrodotoxin | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Tetrodotoxin. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Benzyl alcohol. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Capsaicin. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Etidocaine. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Articaine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Tetracaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Propoxycaine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Pramocaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Butamben. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Butacaine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Oxetacaine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Ethyl chloride. |
| Butanilicaine | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Butanilicaine. |
| Metabutethamine | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Metabutethamine. |
| Quinisocaine | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Quinisocaine. |
| Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Fiacitabine. |
| Ambroxol | The risk or severity of methemoglobinemia can be increased when Fiacitabine is combined with Ambroxol. |
| Etrasimod | The risk or severity of immunosuppression can be increased when Fiacitabine is combined with Etrasimod. |
| Chikungunya vaccine (live, attenuated) | The therapeutic efficacy of Chikungunya vaccine (live, attenuated) can be decreased when used in combination with Fiacitabine. |
| Smallpox (Vaccinia) Vaccine, Live | The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Fiacitabine. |